CD4 and neoplasm: For example, predictive biomarkers such as PD-L1 expression, tumor infiltrating lymphocytes (CD8+, CD4+), tumor mutational burden and chemokines (CXCL 9,11,13) can be used to identify EOC patients that do or do not respond to ICI (111).